Human papillomavirus (HPV) infects large numbers of women worldwide and is present in more than 99% of all cervical cancers. HPV E6 and E7 are two viral oncoproteins that are consistently expressed in HPV infections and HPVassociated malignancies. We have previously developed DNA vaccines encoding calreticulin (CRT) linked either to HPV type 16 (HPV-16) E6 or to HPV-16 E7, both of which generated significant antitumor effects against E6-and E7-expressing tumors. In this study, we demonstrate that simultaneous vaccination of C57BL/6 mice or HLA-A2 transgenic mice with both CRT/E6 and CRT/E7 DNA vaccines generates significant E6-and E7-specific T-cell immune responses in vaccinated mice. Furthermore, combined vaccination with both CRT/E6 and CRT/E7 DNA generates significantly better therapeutic antitumor effects against HPV E6-and E7-expressing tumors than vaccination with either CRT/E6 DNA or CRT/E7 DNA alone. Our data suggest that it may be desirable to combine DNA vaccines targeting E6 with DNA vaccines targeting E7 to develop effective immunotherapeutic strategies for control of HPV infection and HPV-associated lesions in a clinical setting.
Introduction
DNA vaccines are considered a potentially valuable form of antigen-specific immunotherapy because of their safety, ease of production, and stability. The gene gun system can efficiently transduce DNA encoding antigen into professional antigen-presenting cells (APCs), called Langerhans cells, that reside in the epidermis. 1 Transduced APCs express the antigen encoded by the DNA vaccine and present peptides derived from this antigen via the major histocompatability complex (MHC) pathways. These APCs are capable of migrating from the site of vaccination to the draining lymph nodes, where they prime antigen-specific T cells. 2 As the gene gun technique introduces DNA directly into APCs, strategies that target antigen to various subcellular compartments within APCs can be used to enhance antigen presentation by APCs. Previously, we developed several intracellular targeting strategies to enhance DNA vaccine potency against human papillomavirus (HPV), a virus that infects large numbers of women in the world and that is present in more than 99% of all cervical cancers. These targeting strategies enhanced MHC class I and/or MHC class II presentation of HPV E7 antigen by linking E7 to calreticulin (CRT), 3 to Mycobacterium tuberculosis heat-shock protein 70 (HSP70), 4 to the translocation domain of Pseudomonas aeruginosa exotoxin A (ETA(dII)), 5 or to a sorting signal and the lysosome-associated membrane protein I. 6 While each of these four strategies was capable of augmenting E7-specific T-cell responses and antitumor effects in vaccinated mice compared with E7 DNA alone, we observed in a head-to-head comparison that mice vaccinated with CRT linked to E7 generate the highest quantities of E7-specific CD8 + T-cell precursors as well as the highest numbers of E7-specific CD8 + memory T cells, resulting in potent tumor treatment and long-term tumor protection. 7 Our previous studies have focused on vaccinating against HPV type 16 (HPV-16) E7 antigen because HPV-16 is the HPV type most commonly associated with cervical cancer. 8 Furthermore, HPV E7 is an intracellular protein that is consistently expressed throughout HPV infections and HPV-associated malignancies. While vaccination against HPV-16 E7 has been our focus, we have also recently developed a DNA vaccine against HPV-16 E6. 9 HPV E6 represents a second potential target for therapeutic HPV vaccines. Like E7, E6 is an intracellular protein that is consistently expressed in HPV infections and HPV-associated malignances. Both E6 and E7 are required for the induction and maintenance of HPV-associated malignancies (see, for a review, Ellenson and Wu 10 ), making antigen loss for evasion of an immune response to E6 or E7 vaccination highly unlikely for HPV-associated malignancies. Thus, vaccination targeting HPV-16 E6 is an alternate approach to eliciting HPV-specific antitumor effects. In addition, generation of both E6-and E7-specific immunity by vaccination with a combination of E6-and E7-expressing DNA may have a combined therapeutic effect greater than either E6 or E7 vaccination alone.
To test this hypothesis, C57BL/6 mice as well as HLA-A2 transgenic mice were vaccinated with combinations of CRT/E6 and CRT/E7 DNA vaccines and tested for generation of E6-and E7-specific T-cell responses. In addition, vaccination of mice with established E6-and E7-expressing tumors was used to assess tumor treatment effects. We showed that vaccination with CRT/E6 DNA vaccines and CRT/E7 DNA vaccines can generate simultaneous E6-and E7-specific CD8 + T-cell immune responses in vaccinated mice. We also demonstrated that vaccination with the CRT/E6 and CRT/E7 DNA constructs generated the most potent antitumor effects in mice compared to vaccination with CRT/E7 or CRT/E6 DNA alone. The synergistic effects observed when CRT/ E6 and CRT/E7 vaccines are combined may have implications for improving clinical HPV vaccine potency.
Results

DC-1 cells transfected with pcDNA3-CRT/E6 or pcDNA3-CRT/E7 express CRT/E6 or CRT/E7, respectively
To verify that DC-1 cells transfected with pcDNA3-CRT/ E6 or pcDNA3-CRT/E7 constructs are capable of expressing the encoded CRT/E6 or CRT/E7 fusion proteins, respectively, we transiently transfected DC-1 cells with pcDNA3, pcDNA3-CRT, pcDNA3-CRT/E6, or pcDNA3-CRT/E7. Protein extracts from these cells were separated by SDS-PAGE and incubated with either rabbit anti-HPV-16 E6 polyclonal antibody or mouse anti-HPV-16 E7 monoclonal antibody. As seen in Figure 1 , Western blot analysis using anti-HPV-16 E6 antibody revealed a band with approximately the predicted size of CRT/E6 protein present in cell lysate from CRT/E6-transfected cells. Western blot analysis using anti-HPV-16 E7 antibody revealed a band with approximately the predicted size of CRT/E7 protein in cell lysate from CRT/E7-transfected cells. These data indicate that DC-1 cells transfected with CRT/E6 DNA or CRT/E7 DNA were capable of effectively expressing CRT/E6 or CRT/E7.
Vaccination of C57BL/6 mice with pcDNA3-CRT/E6 and/or pcDNA3-CRT/E7 generates E6-and/or E7-specific CD8
+ T-cell immune responses in mice
To explore whether mice vaccinated with pcDNA3-CRT/ E6 and/or pcDNA3-CRT/E7 mount E6-and/or E7-specific CD8 + T-cell immune responses, we used intracellular cytokine staining followed by flow cytometry analysis to determine the number of E6-and/or E7-specific IFN-g-secreting CD8
+ T cells present in vaccinated C57BL/6 mice. As shown in Figure 2 , vaccination with pcDNA3-CRT/E6 and pcDNA3-CRT generated E6-specific IFN-g-secreting CD8
+ T cells only; vaccination with pcDNA3-CRT/E7 and pcDNA3-CRT generated E7-specific IFN-g-secreting CD8 + T cells only; and vaccination with both pcDNA3-CRT/E6 and pcDNA3-CRT/E7 generated both E6-and E7-specific IFN-g-secreting CD8 + T cells. The number of E6-specific T cells generated by mice vaccinated with the combination of pcDNA3-CRT/ E6 and pcDNA3-CRT/E7 was similar to the number of E6-specific T cells generated by vaccination with CRT/E6 and CRT DNA constructs. Likewise, the number of E7-specific T cells generated by mice vaccinated with the combination of CRT/E6 DNA and CRT/E7 DNA was comparable to the number of E7-specific T cells generated by vaccination with CRT/E7 and CRT DNA constructs. Thus, simultaneous vaccination with the two antigen-specific DNA vaccines in two separate locations on the mouse did not diminish the antigenspecific immune response when compared to each of the DNA vaccines administered alone. Our data indicate that CRT/E6 DNA vaccines and CRT/E7 DNA vaccines may be used together without sacrificing the strength of the antigen-specific CD8 + T-cell immune response generated by each of the DNA vaccines administered alone.
Treatment with pcDNA3-CRT/E6 and pcDNA3-CRT/ E7 leads to the greatest reduction of pulmonary tumor nodules in C57BL/6 mice The therapeutic potential of combined pcDNA3-CRT/E6 and pcDNA3-CRT/E7 vaccination was assessed by performing an in vivo tumor treatment experiment using E6-and E7-expressing TC-1 tumor cells in a previously described lung hematogenous spread model. 11 As seen in Figure 3 , C57BL/6 mice treated with both CRT/E6 and CRT/E7 DNA constructs exhibited the lowest mean number of pulmonary tumor nodules (374) compared to mice treated with CRT/E7 DNA and CRT DNA (17712), CRT/E6 DNA and CRT DNA (66711) or CRT DNA alone (117715) (t-test, Po0.05). Notably, the antitumor Combination of HPV E6 and E7 DNA vaccines S Peng et al effects generated by mice vaccinated with CRT/E6 and CRT/E7 are significantly better than the antitumor effects generated by mice vaccinated with CRT/E7 alone (t-test, Po0.05). Mice treated with CRT/E6 DNA and CRT DNA and mice treated with CRT/E7 DNA and CRT DNA developed significantly fewer pulmonary tumor nodules than mice vaccinated with CRT DNA alone (t-test, Po0.01). Furthermore, mice treated with CRT/E7 DNA and CRT DNA exhibited a better therapeutic effect with than mice treated with CRT/E6 DNA and CRT DNA (t-test, Po0.01). These data demonstrate that vaccination with the CRT/E6 and CRT/E7 DNA constructs generated more potent antitumor effects in mice than vaccination with CRT/E7 or CRT/E6 DNA alone, supporting the rationale for simultaneous administration of both CRT/E6 and CRT/E7 DNA vaccines in the clinical arena.
Vaccination with pcDNA3-CRT/E6 and pcDNA3-CRT/ mtE7(del amino-acid (aa)49-57) generates HLA-A2-restricted E6 (aa29-38)-and E7 (aa11-20)-specific CD8 + T-cell immune responses in HLA-A2 transgenic mice HLA transgenic mice may potentially be useful for evaluating HLA-restricted HPV antigen-specific CD8 + Figure 2 Intracellular cytokine staining followed by flow cytometry analysis to determine E6-or E7-specific IFN-g-secretingCD8 + T cells in vaccinated mice. C57BL/6 mice (five per group) were immunized and boosted intradermally via gene gun with the following vaccination groups: (1) pcDNA3-CRT/E6 (2 mg/mouse, right side of the abdomen) and pcDNA3-CRT (2 mg/mouse, left side of the abdomen); (2) pcDNA3-CRT/E7 (2 mg/mouse, right side of the abdomen) and pcDNA3-CRT (2 mg/mouse, left side of the abdomen); or (3) pcDNA3-CRT/ E6 (2 mg/mouse, right side of the abdomen) and pcDNA3-CRT/E7 (2 mg/mouse, left side of the abdomen). Splenocytes were harvested 1 week after the last vaccination and stimulated with either E7 (aa49-57) or E6 (aa50-57) peptide. Splenocytes without peptide stimulation were used as a negative control. The splenocytes were stained for both CD8 and intracellular IFN-g. The numbers on the right upper corner represent the number E7-specific IFN-g-secreting CD8
+ T cells per 3 Â 10 5 splenocytes acquired. The data presented in this figure are from one representative experiment of two performed.
Figure 3
In vivo tumor treatment experiment to compare the antitumor effect generated by various vaccination groups in mice. C57BL/6 mice (five per group) were challenged with 1 Â 10 5 TC-1 tumor cells via tail vein injection. After 3 days, the mice were immunized and boosted as described in the Materials and methods section. At 21 days after tumor challenge, the mice were killed, and the lung tumor nodules were counted. The data are expressed as mean number of lung nodules7s.d. The data shown represent one experiment of two performed.
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T-cell immune responses and for correlating these responses with similar responses observed in humans. 12 We have recently employed HLA-A2 (AAD) transgenic mice to characterize immune responses to E7 DNA vaccines. 13 As HLA-A2 transgenic mice also express murine MHC class I molecules (H-2D b and K b ), when HLA-A2 transgenic mice were vaccinated with DNA encoding CRT linked to wild-type E7, the vaccinated mice generated predominantly H-2D b -restricted E7-specific CD8
+ T-cell immune responses. We observed that the presence of the E7 49-57 aa sequence within the E7 gene of the CRT/E7 DNA vaccine suppresses the efficient activation of HLA-A2 restricted E7 (aa [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] peptide-specific CD8 + T cell-mediated immune responses 13 in HLA-A2 transgenic mice. In order to avoid this situation and accurately characterize the HLA-A2-restricted E7-specific CD8 + T-cell immune response in HLA-A2 transgenic mice, we generated pcDNA3-CRT/ mtE7(del aa49-57), a DNA vaccine that deletes aa49-57 from the E7 gene. We found that vaccination with pcDNA3-CRT/E7(del aa49-57) generates HLA-A2-restricted E7 (aa11-20) peptide-specific CD8 + T-cell immune response in HLA-A2 transgenic mice. 13 In the current study, we characterized the HLA-A2-restricted E6-and/or E7-specific CD8 + T-cell immune responses generated by vaccination with pcDNA3-CRT/ E6 and/or pcDNA3-CRT/mtE7(del aa49-57) in HLA-A2 transgenic mice by intracellular cytokine staining followed by flow cytometry analysis. As shown in Figure 4 , vaccination with pcDNA3-CRT/E6 and pcDNA3-CRT/ mtE7(del aa49-57) generated comparable numbers of HLA-A2-restricted E6 (aa29-38)-specific CD8 + T cells to vaccination with pcDNA3-CRT/E6 without pcDNA3-CRT/mtE7(del aa49-57). Similarly, vaccination with pcDNA3-CRT/E6 and pcDNA3-CRT/mtE7(del aa49-57) generated comparable numbers of HLA-A2-restricted E7 (aa11-20)-specific CD8 + T cells to vaccination with pcDNA3-CRT/mtE7(del aa49-57) without pcDNA3-CRT/E6. Our data indicate that both CRT/E6 DNA vaccines and CRT/mtE7(del aa49-57) DNA vaccines may be used together without compromising the strength of the HLA-A2-restricted antigen-specific CD8 + T-cell immune response generated by each of the DNA vaccines administered alone.
Administration of CRT/E6 and CRT/mtE7(del aa49-57) DNA vaccines mixed in the same bullet generates similar numbers of E6-and E7 -specific CD8 + T cells in HLA-A2 transgenic mice as administration of CRT/E6 and CRT/mtE7(del aa49-57) DNA vaccines in separate bullets
The administration of a DNA vaccine in a clinical setting requires simplicity. Thus, we explored whether vaccination with pcDNA3-CRT/E6 and pcDNA3-CRT/mtE7(del aa49-57) combined in a single bullet would generate E6-and E7-specific HLA-A2-restricted immune responses comparable to vaccination with pcDNA3-CRT/E6 and pcDNA3-CRT/mtE7(del aa49-57) administered in separate bullets. We used intracellular cytokine staining followed by flow cytometry analysis to determine the number of E6-and E7-specific IFN-g-secreting CD8
+ T cells present in vaccinated HLA-A2 transgenic mice. As shown in Figure 5 , mice vaccinated with pcDNA3-CRT/ E6 combined with pcDNA3-CRT/mtE7(del aa49-57) in the same bullet generated comparable numbers of E6-and E7-specific CD8 + T cells to mice vaccinated with pcDNA3-CRT/E6 or pcDNA3-CRT/mtE7(del aa49-57) alone. Taken together, Figures 4 and 5 indicate that administration of both CRT/E6 and CRT/mtE7(del aa49-57) DNA vaccines in one bullet generates comparable numbers of E6-and E7-specific CD8 + T-cell immune responses in HLA-A2 transgenic mice to administration of CRT/E6 and CRT/mtE7(del aa49-57) DNA vaccines in separate bullets.
Discussion
In
a notion has never been rigorously tested in the past. The current manuscript presents the first demonstration that combined vaccination with both CRT/E6 and CRT/E7 DNA generates more potent therapeutic antitumor effects against HPV E6-and E7-expressing tumors than vaccination with either CRT/E6 DNA or CRT/E7 DNA alone. Given the promising results of this study, the strategy of targeting multiple tumor antigens may be of use with other tumor antigens and other tumor models for enhancing the potency of therapeutic tumor vaccines. Our current study serves as an important foundation for future HPV DNA vaccine trials combining both the CRT-E6 and the CRT-E7 DNA vaccines in patients with HPV-associated lesions.
We have demonstrated that coadministration of CRT/ E6 and CRT/E7 DNA vaccines generates a better antitumor effect compared to the administration of CRT/E6 DNA or CRT/E7 DNA supplemented with a plasmid containing CRT. One may contend that coadministration of DNA vaccines may generate twice as much HPV-specific antigen in vaccinated mice as the other two groups, and the design of the experiments should compare vaccination with CRT/E6 and CRT/E7 DNA to vaccination with twice the amount of CRT/E6 DNA or twice the amount of CRT/E7 DNA. However, we have previously shown that the amount of DNA used for intradermal administration via gene gun was not a principal contributor to the antitumor effect in vaccinated mice. Mice receiving different doses of E7 DNA (2, 4, 6, or 8 mg) in two inoculations generated comparable antitumor effects.
14 Our studies demonstrated that it is advantageous to combine vaccines targeting two separate tumor-specific antigens compared to vaccines targeting only one tumor antigen.
In our current experiments, we observed no significant antitumor treatment effects in CRT DNA-vaccinated mice compared to naïve mice in the lung hematogenous spread model (Figure 3) . Previously, however, we demonstrated that CRT DNA vaccination alone generated significant antitumor effects in mice using the lung hematogenous spread model with TC-1 cells. 3 The different results observed in these two experiments can Combination of HPV E6 and E7 DNA vaccines S Peng et al be accounted for by the dose dependent nature of the antitumor effects of CRT. It has been shown that higher doses of CRT can lead to greater antitumor effects. 15 In our previous experiments, a total of 64 mg of CRT DNA was used to generate the antitumor effect observed. However, in the experiments presented in this paper, only a total of 4 mg of CRT DNA was used for control vaccination. This amount was not enough to generate significant antitumor treatment effects in mice. Thus, our data remain consistent when the dose-dependent nature of CRT's antitumor effect is taken into account.
The results of our study show that vaccination with CRT/E7 DNA alone elicits significantly better antitumor responses in C57BL/6 mice than vaccination with CRT/ E6 DNA alone (Figure 3 ). While the true reasons for this effect remain unclear, several factors could potentially account for the different antitumor effects of CRT/E6 and CRT/E7 DNA vaccination. First, E7-specific T cells derived from vaccination with CRT/E7 DNA could differ from E6-specific T cells generated from vaccination with CRT/E6 DNA. For example, the E7-specific T cells could have a higher avidity for E7 antigen presented by ). However, it remains unclear whether CRT is the cause of SLE or simply a molecule against which antibodies are generated as a result of SLE. Additionally, extensive observations from our lab of mice vaccinated with CRT-containing DNA vaccines have identified no evidence of autoimmune reactions in the tissues or organs of vaccinated mice (data not shown). Thus, while concerns about CRT seem warranted, our observations indicate that CRT does not induce autoantibodies or autoimmune reactions in mice.
Another concern is the potential for oncogenicity associated with the use of E6 and E7 proteins in DNA vaccines. To alleviate concerns of oncogenicity associated with administration of E6 and E7 into the body, it will be important to use attenuated versions of E6 and E7 that have been mutated. It has been demonstrated that a mutation at E7 position 24 and/or 26 will disrupt the Rb binding site of E7, abolishing the capacity of E7 to transform cells. 17 Furthermore, mutation at E6 positions 63 or 106 has been shown to destroy several HPV-16 E6 functions, preventing the mutated E6 protein from immortalizing human epithelial cells. 18, 19 Furthermore, clinical translation may preclude the use of the pcDNA3 vector, because it contains an ampicillin resistance gene. We have recently used the pNGVL4a vector for E7 DNA vaccine development. 20 This vector has been previously used for human clinical trials, and would therefore be suitable for clinical translation of E6 DNA vaccines.
In summary, our data suggest that combined vaccination with both CRT/E6 and CRT/E7 DNA generates significantly better therapeutic antitumor effects against HPV E6-and E7-expressing tumors than vaccination with either CRT/E6 DNA or CRT/E7 DNA alone. The preclinical observations suggest that it may be desirable to consider clinical translation of HPV vaccine strategies incorporating DNA vaccines targeting E6 and DNA vaccines targeting E7.
Materials and methods
Plasmid DNA constructs and preparation
The generation of pcDNA3-CRT, 3 pcDNA3-CRT/E6, 9 pcDNA3-CRT/E7, 3 and pcDNA3-CRT/mtE7(del 49-57) 13 have been described previously. All plasmid constructs were confirmed by DNA sequencing. DNA for vaccination was prepared using an endotoxin-free kit (Qiagen, Valencia, CA, USA).
Peptides
Peptides representing defined HPV-16 E7 CTL epitopes, including H-2D b -restricted E7 aa49-57 (RAHYNIVTF), 21 HLA-A*0201-restricted E7 aa11-20 (YMLDLPETT), 22 and HPV-16 E6 CTL epitopes, including H-2Kb-restricted E6 aa50-57 (YDFAFRDL), 9 and HLA-A*0201-restricted E6 aa29-38 (TIHDIILECV), 22 were synthesized by Macromolecular Resources (Denver, CO, USA) at a purity of X70%.
Cells
TC-1 cells were generated as described previously. 23 DC-1 cells were generated from the dendritic cell line 24 provided by Dr Kenneth Rock at the University of Massachusetts. With continued passage, we have generated subclones of DCs (DC-1) that can be easily transfected. 25 All cells were maintained in RPMI medium (Invitrogen, Carlsbad, CA, USA) supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 20 mM HEPES, 50 mM b-mercaptoethanol, 100 IU/ml penicillin, 100 mg/ ml streptomycin, and 10% fetal bovine serum (Gemini Bio-Products, Woodland, CA, USA).
Western blot analysis
DC-1 cells were transiently transfected with pcDNA3-no insert, pcDNA3-CRT, pcDNA3-CRT/E6, and pcDNA3-CRT/E7, respectively, using Lipofectamine 2000 (Gibco, USA). At 24 h after transfection, transfected DC-1 cells were lysed in M-PER Mammalian protein extraction reagent (Pierce, Rockford, IL, USA) based on the manufacturer's instruction. Equal amounts of protein (50 mg) were loaded and separated by SDS-PAGE using a 10% polyacrylamide gel and blotted onto a PVDF membrane. After blocking, the membrane was incubated with either rabbit anti-HPV-16 E6 polyclonal antibody or mouse anti-HPV-16 E7 monoclonal antibody for 2 h at room temperature, washed, and incubated with horseradish peroxidase (HRP)-conjugated donkey anti-rabbit Ig (for E6) (Amersham Biosciences, UK), or HRPconjugated rabbit anti-mouse IgG(H+L) (for E7) (ZYMED, San Francisco, CA, USA). The blot was then washed and detected using chemiluminescence (ECL kit, Amersham, Arlington Heights, IL, USA). Mice C57BL/6 mice (5-8 weeks old) were purchased from the National Cancer Institute. HLA-A*0201/D d (AAD) transgenic female C57BL/6 mice, 6-8 weeks of age, were kindly provided by Dr Victor Engelhard at the University of Virginia Health Sciences Center. 26 These transgenic mice express a chimeric HLA class I molecule, composed of the a-1 and a-2 domains of HLA-A*0201 and the a-3 transmembrane and cytoplasmic domain of H-2D d . This allows the murine CD8 molecule on the murine CD8 + T cells to interact with the syngenic a-3 domain of the chimeric MHC class I molecule. All animals were maintained under specific pathogen-free condition, and all procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
DNA vaccination
Preparation of DNA-coated gold particles and gene gun particle-mediated DNA vaccination was performed using a helium-driven gene gun (BioRad Laboratories Inc., Hercules, CA, USA) according to a protocol described previously. 4 For the immunological assays and in vivo tumor treatment experiment in C57BL/6 mice, mice (five per group) were immunized and boosted intradermally via gene gun with the following vaccination groups: (1) pcDNA3-CRT/E6 (2 mg/mouse, right side of the abdomen) and pcDNA3-CRT (2 mg/ mouse, left side of the abdomen); (2) pcDNA3-CRT/E7 (2 mg/mouse, right side of the abdomen) and pcDNA3-CRT (2 mg/mouse, left side of the abdomen); or (3) pcDNA3-CRT/E6 (2 mg/mouse, right side of the abdomen) and pcDNA3-CRT/E7 (2 mg/mouse, left side of the abdomen). For the immunological assays in HLA-A2
Combination of HPV E6 and E7 DNA vaccines S Peng et al (AAD) transgenic mice, mice (five per group) were immunized and boosted intradermally via gene gun with two different regimens. The first regimen included the following vaccination groups: (1) pcDNA3-CRT/E6 (2 mg/mouse, right side of the abdomen) and pcDNA3-CRT (2 mg/mouse, left side of the abdomen); (2) pcDNA3-CRT/mtE7(del aa49-57) (2 mg/mouse, right side of the abdomen) and pcDNA3-CRT (2 mg/mouse, left side of the abdomen); or (3) pcDNA3-CRT/E6 (2 mg/ mouse, right side of the abdomen) and pcDNA3-CRT/ mtE7(del aa49-57) (2 mg/mouse, left side of the abdomen). The second vaccination regimen in HLA-A2 transgenic mice included the following vaccination groups: (1) pcDNA3-CRT/E6 and pcDNA3-CRT; (2) pcDNA3-CRT/mtE7(del aa49-57) and pcDNA3-CRT; or (3) pcDNA3-CRT/E6 and pcDNA3-CRT/mtE7(del aa49-57). For this regimen, in each vaccination group, the two DNA constructs were mixed in the same bullet and the dose for each construct was 2 mg/mouse. DNA-coated gold particles were delivered to the shaved abdominal region of mice using a helium-driven gene gun (BioRad Laboratories Inc., Hercules, CA, USA) with a discharge pressure of 400 psi.
Intracellular cytokine staining and flow cytometry analysis
Pooled splenocytes from the vaccinated mice were harvested 1 week after the last vaccination and incubated overnight with 1 mg/ml of indicated peptide at the presence of GolgiPlug (BD Pharmingen, San Diego, CA, USA) (1 ml/ml). The peptides tested included D b -restricted E7 (aa49-57), HLA-A2-restricted E7 (aa11-20), Kb-restricted E6 (aa50-57), and HLA-A2-restricted E6 (aa29-38) peptides. The stimulated splenocytes were then washed once with FACScan buffer and stained with phycoerythrin-conjugated monoclonal rat antimouse CD8a (clone 53.6.7). Cells were subjected to intracellular cytokine staining using the Cytofix/Cytoperm kit according to the manufacturer's instruction (BD Pharmingen, San Diego, CA, USA). Intracellular IFN-g was stained with FITC-conjugated rat antimouse IFN-g. All antibodies were purchased from BD Pharmingen. Flow cytometry analysis was performed using FACSCalibur with CELLQuest software (BD Biosciences, Mountain View, CA, USA).
In vivo tumor treatment experiment
For the in vivo tumor treatment experiment, 1 Â 10 5 TC-1 tumor cells were injected into 5-8 weeks old C57BL/6 mice (five per group) via tail vein. After 3 days, the mice were immunized with the DNA vaccines as described above. After 1 week, these mice were boosted once with the same immunization regimen. At 21 days after tumor challenge, the mice were killed, and the lung tumor nodules were counted. Data are expressed as the mean number of lung nodules7standard error (s.e.). The data shown here represent one of the two experiments performed.
Statistical analysis
All data expressed as means7standard deviation (s.d.) are representative of at least two different experiments. Data for intracellular cytokine staining with flow cytometry analysis and tumor treatment experiments were evaluated by analysis of variance. Comparisons between individual data points were made using a Student's t-test. All P-values o0.05 were considered significant.
